XOMA

XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

[at noodls] – BERKELEY, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced preliminary top-line data from an … moreView todays social media effects on XOMAView the latest stocks trending across Twitter. Click to view dashboardSee who XOMA is hiring next, click here to view […]

XOMA Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program

[at noodls] – BERKELEY, Calif., Dec. 31, 2012 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has selected active non-infectious … moreView todays social media effects on XOMAView the latest stocks trending across Twitter. Click to view dashboardSee who XOMA is hiring next, click here to view […]

XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial

[at noodls] – BERKELEY, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA) today announced the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hypertension) has demonstrated … moreView todays social media effects on XOMAView the latest stocks trending across Twitter. Click to view dashboard […]

XOMA Announces Proposed Public Offering of Common Stock

[at noodls] – BERKELEY, Calif., Oct. 23, 2012 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA) announced today it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to … moreView todays social media effects on XOMAView the latest stocks trending across Twitter. Click to view dashboard […]